Genesis Therapeutics
Latest round
- Series B
Last raised
- Aug 2023
Total raised
- $278M
Investors
- 14
About Genesis Therapeutics
Based in California, US, and co-founded by Evan Feinberg (CEO) and Ben Sklaroff (CTO) in 2019, Genesis Therapeutics, Inc. operates as a biotechnology company that offers an AI (artificial intelligence) based molecule discovery platform. Rowe Price Associates. The biotech company is dedicated to advancing therapies and new medicines, protein targets, and exploring untapped chemical species, for patients grappling with severe disorders by leveraging the power of AI and molecular science. Genesis Therapeutics' hallmark product is GEMS, the Genesis Exploration of Molecular Space. GEMS represents the molecular AI platform, fusing deep learning, molecular simulations, and language models for drug discovery. This platform enables the creation of potent and selective small-molecule drugs, targeting previously challenging and undruggable diseases.
Who invested in Genesis Therapeutics
14 investors across 5 rounds
See all investors in Genesis Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Genesis Therapeutics
Who invested in Genesis Therapeutics?
Genesis Therapeutics has 14 investors on record across 5 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Genesis Therapeutics raised?
Genesis Therapeutics has raised 5 venture rounds. Sign up free to see how much each round raised and the total.
When did Genesis Therapeutics last raise money?
Genesis Therapeutics's most recent round on record is a Series B, in Aug 2023.
What does Genesis Therapeutics do?
Based in California, US, and co-founded by Evan Feinberg (CEO) and Ben Sklaroff (CTO) in 2019, Genesis Therapeutics, Inc.
Where is Genesis Therapeutics headquartered?
Genesis Therapeutics is headquartered in Burlingame, US.
Which VCs invest in companies like Genesis Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Genesis Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Genesis Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.